You searched for "clinic"
Emphysematous pyelonephritis: a review
Introduction Emphysematous pyelonephritis (EPN) is an acute, severe, necrotising, bacterial infection of the renal parenchyma and surrounding tissues, with gas in the renal parenchyma, collecting system or perinephric tissue. Although it is rare, it is potentially life threatening and early...Recent developments in bladder cancer – MIBC
This article takes a look back over recent years at new innovations and developments relating to muscle-invasive bladder cancer (MIBC) specifically, and will also touch upon what the future may hold. This article is also written as a continuation of...Conservative management of pelviureteric junction
Background Pelviureteric junction obstruction (PUJO) is defined as a functionally significant impairment of urine flow from the renal pelvis into the proximal ureter. For more than a century, surgery was considered the first-choice approach to management. However, the widespread use...Artificial intelligence in bladder cancer diagnostics
Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...
SUSPEND suspended MET
This review is on the recent groundbreaking evidence on medical expulsive therapy (MET). MET using alpha adrenergic blockers (like tamsulosin) are in regular clinical practice. Even though it is an off label prescription, it is well accepted and practised world...
One cycle of adjuvant chemotherapy in tumours of the testis
Following a radical orchiectomy, current UK practice for newly diagnosed, high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis (NSCGCTT) is either two cycles of adjuvant chemotherapy with bleomycin, etoposide, cisplatin (BE360Px2) or surveillance with BE500Px3 on...
Transurethral en bloc resection versus standard resection of bladder tumour
Bladder cancer is a common urological malignancy, with around 610,000 new cases and 220,000 deaths worldwide in 2022. Approximately 75% of these cases are non-muscle-invasive bladder cancer (NMIBC). The conventional method for treating NMIBC is standard resection (SR), performed transurethrally,...
HOLEP and detrusor underactivity
Lower urinary tract symptoms (LUTS) are common among adult males, significantly influence quality of life (QoL) and contribute to pressure on the NHS. LUTS are conventionally associated with benign prostatic obstruction (BPO), which is commonly observed during the histological progression...Action Bladder Cancer UK – 2019 Report
ABC UK is a national charity working for bladder cancer patients. Set up in 2009 we work to raise awareness of bladder cancer and the issues faced by patients; we provide direct support for patients; we work to improve outcomes for...Action Bladder Cancer UK launches learning module for primary care
Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...
Adjustable Transobturator Male System® as a novel treatment for men with stress urinary incontinence
Stress urinary incontinence (SUI) in men is a debilitating condition, often occurring after prostate cancer surgery, with an incidence ranging from 4% to 40%. Key predictors of SUI post-prostatectomy include age, body mass index (BMI), comorbidity index, lower urinary tract...
